Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

HAEMATOLOGICAL CANCER

Nivolumab effective in treatment-resistant HL

Nature Reviews Clinical Oncology volume 15, page 402 (2018)Cite this article

Subjects

Outcomes of CheckMate 205, a phase II trial, confirm the efficacy of the anti-programmed cell death protein 1 (PD-1) antibody nivolumab in patients with Hodgkin lymphoma (HL) with treatment failure after autologous haematopoietic stem cell transplantation (auto-HSCT), regardless of prior treatment with brentuximab vedotin. A total of 243 patients were divided into three groups based on brentuximab vedotin treatment status: no previous treatment; treatment before auto-HSCT; or treatment after auto-HSCT. An objective response rate of 69% was observed across the entire study cohort, with response rates ≥63% observed in each group and a median progression-free survival duration of 14.7 months. Grade 3–4 adverse events were rare and included increased serum lipase levels (in 5% of patients) and neutropenia (3%). These findings demonstrate that nivolumab is safe and effective in this historically difficult to treat population, regardless of previous treatments received.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

Original Article

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nivolumab effective in treatment-resistant HL. Nat Rev Clin Oncol 15, 402 (2018). https://doi.org/10.1038/s41571-018-0022-2

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-018-0022-2

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing